BASKING RIDGE, N.J., Sept. 25 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, has been selected as a Marquee Presenting Company by the New Jersey Technology Council for its Growth Showcase 2006. As such, VioQuest is one of a select group of companies to present to the entire Growth Company Showcase audience. The conference will take place at the Doubletree Newark Airport Hotel in Elizabeth, NJ. VioQuest will present at 10:00 A.M.
Daniel Greenleaf, president and CEO of VioQuest, will provide a comprehensive company overview and an update on recent corporate and scientific developments. He will discuss VioQuest’s progress with its two targeted cancer agents, VQD-001, currently in Phase I/IIa clinical trials at the Cleveland Clinic, and VQD-002, currently undergoing Phase I/IIa clinical trials at MD Anderson Cancer Center for leukemia and at the Moffitt Cancer Center for solid tumors. VioQuest expects to initiate an additional Phase I/IIa clinical trial at MD Anderson with VQD-001 shortly. In addition, Mr. Greenleaf will discuss the upcoming NDA filing for VQD-001 for Leishmaniasis.
Additional conference information can be found at the New Jersey Technology Council’s website: http://www.njtc.org
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. A pioneer in personalized therapeutics, VioQuest has two targeted oncology compounds in clinical trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers and VQD-002 which has shown to inhibit the phosphorylation of Akt which can be seen in abnormal levels in breast, ovarian, colorectal, pancreatic, and liquid cancers.
VioQuest’s subsidiary Chiral Quest, a leader in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest’s actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “anticipates,” “expects,” “plans,” “believes,” “intends,” and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest’s planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest’s claims, the possibility that VioQuest’s development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest’s product candidates, VioQuest’s reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest’s Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
VioQuest Pharmaceuticals, Inc. Noonan Russo Daniel Greenleaf Investors: Sharon Weinstein Chief Executive Officer 212-845-4271 Brian Lenz Media: Benjamin Carmichael Chief Financial Officer 908-766-4400
VioQuest Pharmaceuticals, Inc.
CONTACT: VioQuest Pharmaceuticals, Inc. - Daniel Greenleaf, ChiefExecutive Officer, or Brian Lenz, Chief Financial Officer, both at+1-908-766-4400, or Noonan Russo - investors, Sharon Weinstein,+1-212-845-4271, or media, Benjamin Carmichael, +1-212-845-4242
Web site: http://www.njtc.org/
